Mycobacterium w immunotherapy for treating pulmonary tuberculosis - A systematic review

Current Pharmaceutical Design

Volumn 20, Issue 39, 2014, Pages 6207-6214

  Pandie, Shaheen ^a   Engel, Mark E ^a   Kerbelker, Zita S ^a   Mayosi, Bongani M ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Immunotherapy; Mycobacterium w; Tuberculosis

Indexed keywords

IMMUNOMODULATING AGENT; MYCOBACTERIUM INDICUS PRANII VACCINE; MYCOBACTERIUM VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DATA BASE; DATA EXTRACTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; LUNG TUBERCULOSIS; MEDICAL EXPERT; MEDLINE; META ANALYSIS; MYCOBACTERIUM INDICUS PRANII; OUTCOME ASSESSMENT; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SPUTUM CULTURE; SPUTUM SMEAR; SYSTEMATIC REVIEW; IMMUNOLOGY; MYCOBACTERIUM; TUBERCULOSIS, PULMONARY;

HUMANS; IMMUNOTHERAPY; MYCOBACTERIUM; TUBERCULOSIS, PULMONARY;

EID: 84911498711     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140905150215     Document Type: Article

References (25)

1. Dheda K, Schwander S, Zhu B, Van Zyl-Smit R, Zhang Y. The immunology of tuberculosis: from bench to bedside. Respirology 2010; 15(3): 433-50.
2. Churchyard G, Kaplan G, Fallows D, Wallis R, Onyebujoh P, Rook G. Advances in immunotherapy for tuberculosis treatment. Clinics in chest medicine. 2009; 30(4): 769-82.
3. Saini V, Raghuvanshi S, Talwar G, Ahmed N, Khurana J, Hasnain S. Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species. PloS one. 2009; 4(7): e6263.
4. Khamar B., Modi RI. Patent application: POLY TLR ANTAGONIST. www. wipo. int/pctdb/en/wo. jsp?wo2008062288 2008. 2008.
5. Chang J, Huggett J, Dheda K, Kim L, Zumla A, Rook G. Myobacterium tuberculosis induces selective up-regulation of TLRs in the mononuclear leukocytes of patients with active pulmonary tuberculosis. Journal of immunology [Internet]. 2006; 176(5): 3010-8. Available from: [PubMed: 16493059].
6. Ganju L, Mukherjee R, Batra H, Talwar G. Immuno-blot analysis of antigens of Mycobacterium w: a candidate anti-leprosy vaccine using monoclonal antibodies and patient sera. Zentralblatt fur Bakteriologie: international journal of medical microbiology. 1990; 273(3): 378-85.
7. Singh I, Mukherjee R, Talwar G. Resistance to intravenous inoculation of Mycobacterium tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on Mycobacterium w. Vaccine. 1991; 9(1): 10-4.
8. Zaheer S, Beena K, Kar H, Sharma A, Misra R, Mukherjee A. Addition of immunotherapy with Mycobacterium w vaccine to multi-drug therapy benefits multi-bacillary leprosy patients. Vaccine. 1995; 13(12): 1102-10.
9. Sharma P, Misra R, Kar H, Mukherjee A, Poricha D, Kaur H. Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multi-bacillary leprosy: a report on hospital based immunotherapeutic clinical trials with a follow-up of 1-7 years after treatment. Leprosy review. 2007; 71(2): 179-92.
10. Kaur I, Dogra S, Kumar B, Radotra B. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multi-bacillary leprosy: a follow-up of 136 patients. International journal of leprosy and other mycobacterial diseases: official organ of the International Leprosy Association. 2002; 70(3): 174-81.
11. Sharma P, Mukherjee R, Talwar G., Sarathchandra K., Walia R, Parida SK, et al. Immunoprophylactic effects of the anti-leprosy M w vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years. Leprosy review. 2005; 76(2): 127-43.
12. Gupta A, Geetha N, Mani J, Upadhyay P, Katoch V, Natrajan M. Immunogenicity and protective efficacy of "Mycobacterium w" against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route. Infection and immunity [Internet]. 2009; 77(1): 223-31. Available from: PubMed: 18981249.
13. Guleria I, Mukherjee R, Kaufmann S. In vivo depletion of CD4 and CD8 T lymphocytes impairs Mycobacterium w vaccine-induced protection against M. tuberculosis in mice. Medical microbiology and immunology. 1993; 182(3): 129-35.
14. Singh I, Mukherjee R, Talwar G, Kaufmann S. In vitro characterization of T cells from Mycobacterium w-vaccinated mice. Infection and immunity. 1992; 60(1): 257-63.
15. Patel N, Deshpande M, Shah M. Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. Journal of the Indian Medical Association [Internet]. 2002; 100(3): 191-3. Available from: PubMed: 12408283.
16. Patel N, Trapathi S. Improved cure rates in pulmonary tuberculosis category II (retreatment) with mycobacterium w. Journal of the Indian Medical Association. 2003; 101(11): 680-2.
17. Luhadia S, Saugat R, Joshi V. Mycobacterium w as an adjuvant to chemotherapy in management of pulmonary tuberculosis. National Conference on Pulmonary Diseases (NAPCON). 2004.
18. Pandie S, Engle M, Kerbelker Z, Mayosi B. Mycobacterium w adjuvant immunotherapy in pulmonary tuberculosis-a systematic review. University of Cape Town; p. Masters in Medicine (MMed) [Thesis] UCT; 2011.
19. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Wiley-Blackwell; 2008.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002; 21(11): 1539-58.
21. Schulz K, Altman D, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Obstetrics and gynaecology. 2010; 115(5): 1063-70.
22. Rieder H. Sputum smear conversion during directly observed treatment for tuberculosis. Tubercle and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 1996; 77(2): 124-9.
23. NCT00265226. Efficacy and safety study of immunomodulator (Mycobacteriumw) as an adjunct therapy in category-II pulmonary tuberculosis along with assessment of immunological parameters.
24. NCT00341328. Efficacy and safety of immunomodulator (Mycobacteriumw) as an adjunct therapy in category I pulmonary tuberculosis and along with assessment of immunological parameters.
25. Mayosi BM, Ntsekhe M, Bosch J, et al. Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: A 2 ◊ 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis. Am Heart J 2013; 165(2): 109-15. e3.